The Competitive Implications of Generic Biologics and Biosimilars

Generic biologics – or biosimilars – are a new generation of pharmaceuticals. Companies ranging from established biopharma innovators and start-up biotechs to traditional small molecule generic houses are examining how to exploit the opportunities and defend against the challenges that will result from the introduction of biosimilars in the U.S. market. Biosimilars are likely to present tremendous competitive pressure and opportunities once a regulatory pathway is established in the United States.
A topic of interest to life sciences companies and executives of all types, please join us for an interactive discussion and guide to navigating the emerging development, production and regulation of biosimilars.

Our diverse panel of industry experts will explore:

• What are biosimilars? How will they affect my business?
• What is the status of current legislation? How will it impact innovative and biosimilar companies?
• How are companies preparing for biosimilar product development and introduction?
• What offensive/defensive strategies will best position my company?

Agenda
8:00AM - 8:30AM: Breakfast and Networking
8:30AM - 10:00AM: Panel Discussion

Speakers:
Christopher Seaton
Senior Vice President, Global Transactions
Bayer HealthCare Pharmaceuticals


Christopher Slavinsky
Assistant General Counsel
Pfizer, Inc.


Marta Gross
Partner
Goodwin Procter LLP

Kevin Collins (Moderator)
Partner
Goodwin Procter LLP